Cargando…

Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain

BACKGROUND: Chronic pain is a prevalent condition in the United States. Musculoskeletal pain, including joint and back pain, is the most common type of chronic pain, and many patients with back pain have a neuropathic component. Pain has direct economic consequences. While oxycodone controlled-relea...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastassopoulos, Kathryn P., Chow, Wing, Tapia, Crisanta I., Baik, Rebecca, Ackerman, Stacey J., Biondi, David, Kim, Myoung S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437335/
https://www.ncbi.nlm.nih.gov/pubmed/23127149
http://dx.doi.org/10.18553/jmcp.2012.18.8.615
_version_ 1785092498467586048
author Anastassopoulos, Kathryn P.
Chow, Wing
Tapia, Crisanta I.
Baik, Rebecca
Ackerman, Stacey J.
Biondi, David
Kim, Myoung S.
author_facet Anastassopoulos, Kathryn P.
Chow, Wing
Tapia, Crisanta I.
Baik, Rebecca
Ackerman, Stacey J.
Biondi, David
Kim, Myoung S.
author_sort Anastassopoulos, Kathryn P.
collection PubMed
description BACKGROUND: Chronic pain is a prevalent condition in the United States. Musculoskeletal pain, including joint and back pain, is the most common type of chronic pain, and many patients with back pain have a neuropathic component. Pain has direct economic consequences. While oxycodone controlled-release (CR) is one of the most widely used oral long-acting opioids for pain, including pain with a neuropathic component, it is often associated with bothersome side effects, resulting in additional medical resource use (MRU) and costs. OBJECTIVES: To examine the impact on MRU and costs to payers of side effects in patients taking oxycodone CR alone or in combination with other pain medications for noncancer pain (including those with neuropathic pain symptoms). METHODS: A nationwide convenience sample of adults in the United States, who participated in a survey research panel and reported current use of oxycodone CR for noncancer pain, completed an online survey between November 2, 2010, and December 13, 2010. Respondents were excluded if they reported current use of other extended-release or long-acting opioid prescription medications. The survey consisted of questions on demographics, clinical characteristics, pain characteristics, experience with pain medication, and MRU associated with side effects. Payer costs were calculated based on the MRU reported by the respondents multiplied by Medicare reimbursement rates for hospitalizations and outpatient visits and average wholesale price (AWP) minus 20% for medications. A subgroup of patients who reported neuropathic pain symptoms also was examined. RESULTS: After applying the exclusion criteria, 432 respondents completed the survey. Approximately half of the respondents (n = 219; 50.7%) reported neuropathic pain symptoms. The majority of respondents were Caucasian (88.4%) and female (63.7%) with an average age of 41.8 years (14.89). Respondents most frequently reported low back pain (41.2%), followed by osteoarthritis/rheumatoid arthritis (20.4%), neuropathic pain (10.6%), and fibromyalgia (9.0%). Respondents reported having their pain condition for an average of 5.4 (7.42) years. On days when taken, respondents reported a mean oxycodone CR daily dose of 83.3 mg (126.93) taken in an average of 2 doses. Most respondents (82.4%) reported experiencing at least 1 side effect with 77.5% being bothered by at least 1 side effect. The most frequently reported side effects ( greater than 25%) were drowsiness (41.4%), constipation (37.0%), fatigue or daytime sleepiness (36.6%), and dizziness (27.1%). Among respondents who reported being bothered by one or more side effects in the previous month, MRU associated with side effects was reported by 39.1% of respondents and significantly increased as the level of side-effect bother increased from 19.8% among those “A little bit bothered” to 38.4% among those “Bothered” to 61.0% among those “Extremely bothered” (P  less than  0.001). Additionally, total average payer costs (in 2010 dollars) per respondent in the previous month associated with side effects were $238 ($1,159) and also significantly increased as the level of side-effect bother increased from $61 ($512) among those “A little bit bothered” to $238 ($1,160) among those “Bothered” to $425 ($1,561) among those “Extremely bothered” (P  less than  0.001). Results reported in the neuropathic pain subgroup were similar to results reported in the total study sample. CONCLUSIONS: Among adults taking oxycodone CR for chronic noncancer pain (with or without a neuropathic pain component), over three-fourths reported being bothered by side effects. Respondents who reported higher levels of side-effect bother also reported greater MRU, resulting in increased payer costs. The results of this study provide further support of the econo-mic burden to payers associated with opioid-related side effects in patients with chronic noncancer pain, with and without neuropathic pain.
format Online
Article
Text
id pubmed-10437335
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104373352023-08-21 Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain Anastassopoulos, Kathryn P. Chow, Wing Tapia, Crisanta I. Baik, Rebecca Ackerman, Stacey J. Biondi, David Kim, Myoung S. J Manag Care Pharm Research BACKGROUND: Chronic pain is a prevalent condition in the United States. Musculoskeletal pain, including joint and back pain, is the most common type of chronic pain, and many patients with back pain have a neuropathic component. Pain has direct economic consequences. While oxycodone controlled-release (CR) is one of the most widely used oral long-acting opioids for pain, including pain with a neuropathic component, it is often associated with bothersome side effects, resulting in additional medical resource use (MRU) and costs. OBJECTIVES: To examine the impact on MRU and costs to payers of side effects in patients taking oxycodone CR alone or in combination with other pain medications for noncancer pain (including those with neuropathic pain symptoms). METHODS: A nationwide convenience sample of adults in the United States, who participated in a survey research panel and reported current use of oxycodone CR for noncancer pain, completed an online survey between November 2, 2010, and December 13, 2010. Respondents were excluded if they reported current use of other extended-release or long-acting opioid prescription medications. The survey consisted of questions on demographics, clinical characteristics, pain characteristics, experience with pain medication, and MRU associated with side effects. Payer costs were calculated based on the MRU reported by the respondents multiplied by Medicare reimbursement rates for hospitalizations and outpatient visits and average wholesale price (AWP) minus 20% for medications. A subgroup of patients who reported neuropathic pain symptoms also was examined. RESULTS: After applying the exclusion criteria, 432 respondents completed the survey. Approximately half of the respondents (n = 219; 50.7%) reported neuropathic pain symptoms. The majority of respondents were Caucasian (88.4%) and female (63.7%) with an average age of 41.8 years (14.89). Respondents most frequently reported low back pain (41.2%), followed by osteoarthritis/rheumatoid arthritis (20.4%), neuropathic pain (10.6%), and fibromyalgia (9.0%). Respondents reported having their pain condition for an average of 5.4 (7.42) years. On days when taken, respondents reported a mean oxycodone CR daily dose of 83.3 mg (126.93) taken in an average of 2 doses. Most respondents (82.4%) reported experiencing at least 1 side effect with 77.5% being bothered by at least 1 side effect. The most frequently reported side effects ( greater than 25%) were drowsiness (41.4%), constipation (37.0%), fatigue or daytime sleepiness (36.6%), and dizziness (27.1%). Among respondents who reported being bothered by one or more side effects in the previous month, MRU associated with side effects was reported by 39.1% of respondents and significantly increased as the level of side-effect bother increased from 19.8% among those “A little bit bothered” to 38.4% among those “Bothered” to 61.0% among those “Extremely bothered” (P  less than  0.001). Additionally, total average payer costs (in 2010 dollars) per respondent in the previous month associated with side effects were $238 ($1,159) and also significantly increased as the level of side-effect bother increased from $61 ($512) among those “A little bit bothered” to $238 ($1,160) among those “Bothered” to $425 ($1,561) among those “Extremely bothered” (P  less than  0.001). Results reported in the neuropathic pain subgroup were similar to results reported in the total study sample. CONCLUSIONS: Among adults taking oxycodone CR for chronic noncancer pain (with or without a neuropathic pain component), over three-fourths reported being bothered by side effects. Respondents who reported higher levels of side-effect bother also reported greater MRU, resulting in increased payer costs. The results of this study provide further support of the econo-mic burden to payers associated with opioid-related side effects in patients with chronic noncancer pain, with and without neuropathic pain. Academy of Managed Care Pharmacy 2012-10 /pmc/articles/PMC10437335/ /pubmed/23127149 http://dx.doi.org/10.18553/jmcp.2012.18.8.615 Text en Copyright © 2012, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research
Anastassopoulos, Kathryn P.
Chow, Wing
Tapia, Crisanta I.
Baik, Rebecca
Ackerman, Stacey J.
Biondi, David
Kim, Myoung S.
Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain
title Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain
title_full Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain
title_fullStr Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain
title_full_unstemmed Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain
title_short Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain
title_sort economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437335/
https://www.ncbi.nlm.nih.gov/pubmed/23127149
http://dx.doi.org/10.18553/jmcp.2012.18.8.615
work_keys_str_mv AT anastassopouloskathrynp economicstudyontheimpactofsideeffectsinpatientstakingoxycodonecontrolledreleasefornoncancerpain
AT chowwing economicstudyontheimpactofsideeffectsinpatientstakingoxycodonecontrolledreleasefornoncancerpain
AT tapiacrisantai economicstudyontheimpactofsideeffectsinpatientstakingoxycodonecontrolledreleasefornoncancerpain
AT baikrebecca economicstudyontheimpactofsideeffectsinpatientstakingoxycodonecontrolledreleasefornoncancerpain
AT ackermanstaceyj economicstudyontheimpactofsideeffectsinpatientstakingoxycodonecontrolledreleasefornoncancerpain
AT biondidavid economicstudyontheimpactofsideeffectsinpatientstakingoxycodonecontrolledreleasefornoncancerpain
AT kimmyoungs economicstudyontheimpactofsideeffectsinpatientstakingoxycodonecontrolledreleasefornoncancerpain